Basiliximab induction therapy for live donor kidney transplantation: a long-term follow-up of prospective randomized controlled study
Tóm tắt
The effect of basiliximab induction therapy on long-term patient and graft survival is not yet clear. We aimed to evaluate if there is any advantage of routine basiliximab induction on the long-term outcome of living related donor kidney transplantation. One hundred adult recipients with their first kidney allograft were randomized into two treatment groups, one group received basiliximab and the second served as a control. All patients received a maintenance triple immunosuppressive therapy (steroids, cyclosporine (CsA) micro-emulsion and azathioprinep) and were followed up thoroughly for 7 years. Basiliximab significantly reduced the proportion of patients who experienced acute rejection in the first year (18/50) when compared to the control group (31/50), and in 7 years (28/50) when compared to (37/50) in controls. The cumulative steroid dose used throughout the whole study period was significantly lower in the basiliximab group. The overall incidence of post-transplant complications was comparable among the two treatment groups. There was no significant difference in patient or graft survival; 7 years patient and graft survival were 92, 76% for basiliximab and 92, 80% for the control group, respectively. Routine basiliximab induction significantly reduced the incidence of acute rejection without any noticeble beneficial effect on the long-term renal transplantation outcome.
Tài liệu tham khảo
Sollinger H, Kaplan B, Pescovitz M, Philosophe B, Roza A, Brayman K, Somberg K. Basiliximab versus antithymocyte globulin for prevention of acute renal allograft rejection. Transplantation. 2001;72:1915–9.
Brennan DC, Flavin K, Lowell JA, Howard TK, Shenoy S, Burgess S, Dolan S, Kano JM, Mahon M, Schnitzler MA, Woodward R, Irish W, Singer GG. A randomized, double-blinded comparison of thymogloublin versus ATGAM for induction immunosuppressive therapy in adult renal transplant recipients. Transplantation. 1999;67:1011–8.
Bock HA, Gallati H, Zürcher RM, Bachofen M, Mihatsch MJ, Landmann J, Thiel G. A randomized prospective trial of prophylactic immunosuppression with ATG-Fresenius versus OKT3 after renal transplantation. Transplantation. 1995;59:830–40.
Yussin A, Shapira Z. Single-bolus high—dose ATG for prophylaxis of rejection in renal transplantation- a prospective, randomized study. Transplant Int. 2000;13:S293–4.
Henry ML. Induction therapy. Curr Opin Organ Transplant. 1997;2:49–53.
Danovitch GM. Immunosuppressive medications and protocols for kidney transplantation. In: GM Danovitch, editor. Handbook of Kidnet Transplantation, 4th edn. 2005. pp 72–134.
Maes BD, Vanrenterghem YF. Anti-interleukin-2 receptor monoclonal antibodies in renal transplantation: Editorial comments. Nephrol Dial Transplant. 1999;14:2824–6.
Olyaei AJ, Thi K, Le Mattas AM, Bennett WM. Use of basiliximab and daclizumab in kidney transplantation. Prog Transplant. 2001;1:33–9.
Nashan B, Light S, Hardie IR, Lin A, Johnson RJ. Reduction of acute renal allograft rejection by daclizumab. Transplantation. 1999;67:110–5.
Nashan B, Moore R, Amlot P, Schmidt AG, Abeywickrama K, Soulillou JP. Randomized trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. Lancet. 1997;350:1193–8.
Kahan BD, Rajagopalan PR, Hall M. Reduction of the occurrence of acute cellular rejection among renal allograft recipients treated with basiliximab, a chimeric anti-interleukin-2-receptor monoclonal antibody. Transplantation. 1999;67:276–84.
Mulloy LL, Wright F, Hall ML, Moore M. Simulect (Basiliximab) reduces acute cellular rejection in renal allografts from cadaveric and living donors. Transplant Proc. 1999;31:1210–3.
Sheashaa HA, Bakr MA, Ismail AM, Sobh MA, Ghoneim MA. Basiliximab reduces the incidence of acute cellular rejection in live-related-donor kidney transplantation: a three-year prospective randomized trial. J Nephrol. 2003;16(3):393–8.
Sheashaa HA, Bakr MA, Ismail AM, Gheith OE, El-dahshan KF, Sobh MA, Ghoneim MA. Long-term evaluation of basiliximab induction therapy in live donor kidney transplantation: a five-year prospective randomized study. Am J Nephrol. 2005;25(3):221–5.
Buyse I, Decorte R, Cuppens H. Rapid DNA typing of class II HLA antigens using the polymerase chain reaction and reverse dot blot hybridization. Tissue Antigens. 1993;48:1.
Racusen L, Solez K, Colvin R, Bonsib S, et al. The Banff 97 working classification of renal allograft pathology. Kidney Int. 1999;55:713–23.
Onrust SV, Wiseman LR. Basiliximab. Drugs. 1999;57(2):207–13.
Ponticelli C, Yussim A, Cambi V, Legendre C, Rizzo G, et al. Basiliximab significantly reduces acute rejection in renal transplant patients given triple therapy with azathioprine. Transplant Proc. 2001;33:1009–10.
Offner G, Broyer M, Niaudet P, Loirat C, Mentser M, et al. A multicenter, open-label, pharmacokinetic/pharmacodynamic safety, and tolerability study of basiliximab (Simulect) in pediatric de novo renal transplant recipients. Transplantation. 2002;74(7):961–6.
Grenda R, Watson A, Vondrak K, Webb NJ, Beattie J, et al. A prospective, randomized, multicenter trial of tacrolimus-based therapy with or without basiliximab in pediatric renal transplantation. Am J Transplant. 2006;7:1666–72.
Webster AC, Playford EG, Higgins G, Chapman JR, Craig JC. Interleukin 2 receptor antagonists for renal transplant recipients: a meta-analysis of randomized trials. Transplantation. 2004;77(2):166–76.